# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and maintains $...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...
B. Riley Securities analyst Kalpit Patel maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price t...
Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from ...
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...
Wedbush analyst Laura Chico maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and lowers the price target ...
Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.56) per share which missed the analyst consensus estim...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...